Erytech collaborates on rare disease drug; Enterome creates diagnostics venture with Nestlé
⟶ France’s Erytech has forged a collaboration with Queen’s University in Canada on their eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism. “This is our second collaboration in the field of rare metabolic diseases that underscores the scope of our platform and its applicability to highly specialized and rare conditions beyond oncology,” said CSO Alexander Scheer.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters